Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis ; volume:40 ; number:10 ; day:12 ; month:8 ; year:2023 ; pages:4117-4126 ; date:10.2023
Advances in therapy ; 40, Heft 10 (12.8.2023), 4117-4126, 10.2023

Creator: Liu, Geoffrey
Lam, Vincent K.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s12325-023-02606-x

URN: urn:nbn:de:101:1-2023112713093475035039

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:24 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Liu, Geoffrey
Lam, Vincent K.
SpringerLink (Online service)

Other Objects (12)

Alecensa bei ALK-positivem NSCLC

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC

Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC

Alecensa bei ALK-positivem NSCLC

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC

Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC

Alecensa bei ALK-positivem NSCLC

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC

Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Alecensa bei ALK-positivem NSCLC

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC

Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC

Alecensa bei ALK-positivem NSCLC

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC

Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC

Alecensa bei ALK-positivem NSCLC

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC

Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC

Related objects

Reset password